Skip to main content
Top
Published in: Cancer Causes & Control 5/2009

01-07-2009 | Original Paper

Past medical conditions and K-ras mutations in pancreatic ductal adenocarcinoma: a hypothesis-generating study

Authors: Marta Crous-Bou, Miquel Porta, Eva Morales, Tomàs López, Alfredo Carrato, Elisa Puigdomènech, Francisco X. Real, PANKRAS II Study Group

Published in: Cancer Causes & Control | Issue 5/2009

Login to get access

Abstract

Background

In pancreatic ductal adenocarcinoma (PDA) evidence on the etiopathogenic role of past medical conditions in the occurrence and persistence of K-ras mutations is scant.

Methods

Incident cases of PDA were interviewed face-to-face about past medical history and other factors. Logistic regression was used to compare PDA cases (n = 120) with wild-type and mutated K-ras tumors (case–case study).

Results

Patients with wild-type K-ras tumors were more likely to have a prior diagnosis of pancreatitis (Odds ratio [OR] = 6.11, p = 0.041). Diabetes mellitus (DM) was non-significantly more common among cases with a K-ras wild-type tumor, and the OR for DM of >6 years of duration was 4.54 (p = 0.39). Patients with wild-type K-ras were significantly more likely to have had a surgically treated peptic ulcer (OR = 9.03, p = 0.027). The probability of having a K-ras wild-type tumor increased with the number of medical conditions (p for trend = 0.012); the corresponding OR for two or more medical conditions was 4.46 (95% CI: 1.37–14.50).

Conclusions

Results raise the hypothesis that pancreatitis and possibly peptic ulcer might influence pancreatic carcinogenesis through pathways independent of K-ras mutation, perhaps related to growth factors or mediators of the inflammatory response. Large unselected studies should be conducted to refute or replicate our findings.
Literature
1.
go back to reference Ekbom A, Hunter D (2002) Pancreatic cancer. In: Adami HO, Hunter D, Trichopoulos D (eds) Textbook of cancer epidemiology. Oxford University Press, New York, pp 233–247 Ekbom A, Hunter D (2002) Pancreatic cancer. In: Adami HO, Hunter D, Trichopoulos D (eds) Textbook of cancer epidemiology. Oxford University Press, New York, pp 233–247
2.
go back to reference Li D, Jiao L, Porta M (2005) Epidemiology. In: von Hoff DD, Evans DB, Hruban RH (eds) Pancreatic cancer. Jones & Bartlett, Boston, pp 103–117 Li D, Jiao L, Porta M (2005) Epidemiology. In: von Hoff DD, Evans DB, Hruban RH (eds) Pancreatic cancer. Jones & Bartlett, Boston, pp 103–117
3.
go back to reference Hassan MM, Bondy ML, Wolff RA et al (2007) Risk factors for pancreatic cancer: case–control study. Am J Gastroenterol 102:2696–2707PubMedCrossRef Hassan MM, Bondy ML, Wolff RA et al (2007) Risk factors for pancreatic cancer: case–control study. Am J Gastroenterol 102:2696–2707PubMedCrossRef
7.
8.
go back to reference Gandini S, Lowenfels AB, Jaffee EM, Armstrong TD, Maisonneuve P (2005) Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms. Cancer Epidemiol Biomarkers Prev 14:1908–1916. doi:10.1158/1055-9965.EPI-05-0119 PubMedCrossRef Gandini S, Lowenfels AB, Jaffee EM, Armstrong TD, Maisonneuve P (2005) Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms. Cancer Epidemiol Biomarkers Prev 14:1908–1916. doi:10.​1158/​1055-9965.​EPI-05-0119 PubMedCrossRef
10.
go back to reference Efthimiou E, Crnogorac-Jurcevic T, Lemoine NR, Brentnall TA (2001) Inherited predisposition to pancreatic cancer. Gut 48:143–147PubMedCrossRef Efthimiou E, Crnogorac-Jurcevic T, Lemoine NR, Brentnall TA (2001) Inherited predisposition to pancreatic cancer. Gut 48:143–147PubMedCrossRef
13.
18.
19.
go back to reference Slebos RJ, Hoppin JA, Tolbert PE et al (2000) K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol Biomarkers Prev 9:1223–1232PubMed Slebos RJ, Hoppin JA, Tolbert PE et al (2000) K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol Biomarkers Prev 9:1223–1232PubMed
20.
go back to reference Fryzek JP, Garabrant DH, Schenk M, Kinnard M, Greenson JK, Sarkar FH (2006) The association between selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations. Int J Gastrointest Cancer 37:139–145PubMed Fryzek JP, Garabrant DH, Schenk M, Kinnard M, Greenson JK, Sarkar FH (2006) The association between selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations. Int J Gastrointest Cancer 37:139–145PubMed
24.
go back to reference Sparmann A, Bar-Sagi D (2005) Ras oncogene and inflammation: partners in crime. Cell Cycle 4:735–736PubMed Sparmann A, Bar-Sagi D (2005) Ras oncogene and inflammation: partners in crime. Cell Cycle 4:735–736PubMed
26.
go back to reference Basso D, Plebani M, Fogar P et al (1995) Insulin-like growth factor-I, interleukin-1 alpha and beta in pancreatic cancer: role in tumor invasiveness and associated diabetes. Int J Clin Lab Res 25:40–43. doi:10.1007/BF02592575 PubMedCrossRef Basso D, Plebani M, Fogar P et al (1995) Insulin-like growth factor-I, interleukin-1 alpha and beta in pancreatic cancer: role in tumor invasiveness and associated diabetes. Int J Clin Lab Res 25:40–43. doi:10.​1007/​BF02592575 PubMedCrossRef
28.
go back to reference Porta M, Malats N, Guarner L et al (1999) Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. J Epidemiol Community Health 53:702–709PubMedCrossRef Porta M, Malats N, Guarner L et al (1999) Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. J Epidemiol Community Health 53:702–709PubMedCrossRef
29.
go back to reference Malats N, Casals T, Porta M, Guarner L, Estivill X, Real FX (2001) The cystic fibrosis transmembrane regulator (CFTR) ΔF508 mutation and 5T allele in patients with chronic pancreatitis and exocrine pancreas cancer. Gut 48:70–74PubMedCrossRef Malats N, Casals T, Porta M, Guarner L, Estivill X, Real FX (2001) The cystic fibrosis transmembrane regulator (CFTR) ΔF508 mutation and 5T allele in patients with chronic pancreatitis and exocrine pancreas cancer. Gut 48:70–74PubMedCrossRef
30.
go back to reference Alguacil J, Porta M, Malats N et al (2002) Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer. Carcinogenesis 23:101–106PubMedCrossRef Alguacil J, Porta M, Malats N et al (2002) Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer. Carcinogenesis 23:101–106PubMedCrossRef
31.
go back to reference Real FX, Malats N, Lesca G et al (2002) Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreas cancer. Gut 50:653–657PubMedCrossRef Real FX, Malats N, Lesca G et al (2002) Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreas cancer. Gut 50:653–657PubMedCrossRef
32.
go back to reference Porta M, Fabregat X, Malats N et al (2005) Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 7:189–197PubMedCrossRef Porta M, Fabregat X, Malats N et al (2005) Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 7:189–197PubMedCrossRef
33.
go back to reference Soler M, Malats N, Porta M et al (1999) Medical conditions in patients with pancreatic and biliary diseases: validity and agreement between data from questionnaires and medical records. Dig Dis Sci 44:2469–2477PubMedCrossRef Soler M, Malats N, Porta M et al (1999) Medical conditions in patients with pancreatic and biliary diseases: validity and agreement between data from questionnaires and medical records. Dig Dis Sci 44:2469–2477PubMedCrossRef
34.
go back to reference Soler M, Porta M, Malats N et al (1998) Learning from case-reports: diagnostic issues in an epidemiologic study of pancreatic cancer. J Clin Epidemiol 51:1215–1221PubMedCrossRef Soler M, Porta M, Malats N et al (1998) Learning from case-reports: diagnostic issues in an epidemiologic study of pancreatic cancer. J Clin Epidemiol 51:1215–1221PubMedCrossRef
35.
go back to reference Gavaldà L, Porta M, Malats N et al (1995) Agreement between information supplied by the patient and a family member on medical history, consumption of tobacco, alcohol and coffee and diet in cancer of the exocrine pancreas and extrahepatic biliary tract. Gac Sanit 9:334–342PubMed Gavaldà L, Porta M, Malats N et al (1995) Agreement between information supplied by the patient and a family member on medical history, consumption of tobacco, alcohol and coffee and diet in cancer of the exocrine pancreas and extrahepatic biliary tract. Gac Sanit 9:334–342PubMed
38.
go back to reference Armitage P, Berry G, Matthews JNS (2002) Statistical methods in medical research, 4th edn. Blackwell, Oxford Armitage P, Berry G, Matthews JNS (2002) Statistical methods in medical research, 4th edn. Blackwell, Oxford
39.
go back to reference Rothman KJ, Greenland S, Lash TL (eds) (2008) Modern epidemiology, 3rd edn. Lippincott-Raven, Philadelphia Rothman KJ, Greenland S, Lash TL (eds) (2008) Modern epidemiology, 3rd edn. Lippincott-Raven, Philadelphia
40.
go back to reference Bland M (1987) An introduction to medical statistics. Oxford Medical Publications, Oxford, pp 241–265 Bland M (1987) An introduction to medical statistics. Oxford Medical Publications, Oxford, pp 241–265
41.
go back to reference Ren YX, Xu GM, Li ZS, Song YG (2004) Detection of point mutation in K-ras oncogene at codon 12 in pancreatic diseases. World J Gastroenterol 10:881–884PubMed Ren YX, Xu GM, Li ZS, Song YG (2004) Detection of point mutation in K-ras oncogene at codon 12 in pancreatic diseases. World J Gastroenterol 10:881–884PubMed
42.
go back to reference Gansauge S, Schmid RM, Muller J, Adler G, Mattfeldt T, Beger HG (1998) Genetic alterations in chronic pancreatitis: evidence for early occurrence of p53 but not K-ras mutations. Br J Surg 85:337–340PubMedCrossRef Gansauge S, Schmid RM, Muller J, Adler G, Mattfeldt T, Beger HG (1998) Genetic alterations in chronic pancreatitis: evidence for early occurrence of p53 but not K-ras mutations. Br J Surg 85:337–340PubMedCrossRef
43.
go back to reference Luttges J, Diederichs A, Menke MA, Vogel I, Kremer B, Kloppel G (2000) Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53. Cancer 88:2495–2504PubMedCrossRef Luttges J, Diederichs A, Menke MA, Vogel I, Kremer B, Kloppel G (2000) Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53. Cancer 88:2495–2504PubMedCrossRef
44.
go back to reference Löhr M, Kloppel G, Maisonneuve P, Lowenfels AB, Luttges J (2005) Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 7:17–23. doi:10.1593/neo.04445 PubMedCrossRef Löhr M, Kloppel G, Maisonneuve P, Lowenfels AB, Luttges J (2005) Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 7:17–23. doi:10.​1593/​neo.​04445 PubMedCrossRef
49.
go back to reference Porta M, Malats N, Vioque J et al (2002) Incomplete overlapping of biological, clinical and environmental information in molecular epidemiologic studies: a variety of causes and a cascade of consequences. J Epidemiol Community Health 56:734–738. doi:10.1136/jech.56.10.734 PubMedCrossRef Porta M, Malats N, Vioque J et al (2002) Incomplete overlapping of biological, clinical and environmental information in molecular epidemiologic studies: a variety of causes and a cascade of consequences. J Epidemiol Community Health 56:734–738. doi:10.​1136/​jech.​56.​10.​734 PubMedCrossRef
Metadata
Title
Past medical conditions and K-ras mutations in pancreatic ductal adenocarcinoma: a hypothesis-generating study
Authors
Marta Crous-Bou
Miquel Porta
Eva Morales
Tomàs López
Alfredo Carrato
Elisa Puigdomènech
Francisco X. Real
PANKRAS II Study Group
Publication date
01-07-2009
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 5/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9267-x

Other articles of this Issue 5/2009

Cancer Causes & Control 5/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine